Yuji Shishido

USPTO Granted Patents = 18 (Patent Applications = 5)

CIPO Patents = 5 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 4)

Average Co-Inventor Count = 3.8

ph-index = 4

Forward Citations = 39(Granted Patents)

Location History:

Chita, JP (1995)
Aichi-ken, JP (1998 - 2011)
Chita-gun, JP (2000 - 2012)
Aichi, JP (2014 - 2021)

Company Filing History:

Warner-lambert Company

patents

4. 1 out of 28

Xuanzhu Pharma Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 1995-2024

Loading Chart...

18 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12110287 - Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers (2024-10-08),

2. 11154544 - Amide derivatives as Nav1.7 and Nav1.8 blockers (2021-10-26),

3. 11020381 - Biaryloxy derivatives as TTX-S blockers (2021-06-01),

4. 10093678 - Azaspiro derivatives as TRPM8 antagonists (2018-10-09),

5. 8829026 - Sulfamoyl benzoic acid heterobicyclic derivatives as TRPM8 antagonists (2014-09-09),

6. 8252790 - [object Object] (2012-08-28),

7. 8178558 - Substituted pyridylmethyl bicycliccarboxyamide compounds (2012-05-15),

8. 7915448 - Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists (2011-03-29),

9. 7622589 - Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists (2009-11-24),

10. 7566739 - Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists (2009-07-28),

11. 7514457 - Substituted aryloxymethyl bicyclicmethyl acetamide compounds (2009-04-07),

12. 6653313 - 1,4-dihydropyridine compounds as bradykinin antagonists (2003-11-25),

13. 6506775 - Substituted benzylaminopiperidine compounds (2003-01-14),

14. 6444677 - 5-membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists (2002-09-03),

15. 6329396 - Substituted benzylaminopiperidine compounds (2001-12-11),

Title: The Innovations of Yuji Shishido

Introduction

Yuji Shishido is a prominent inventor based in Aichi-ken, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target voltage-gated sodium channels. With a total of 18 patents to his name, Shishido's work has the potential to impact the treatment of various disorders and diseases.

Latest Patents

Among his latest patents are two notable inventions: "Heterocyclic derivatives as Nav1.7 and Nav1.8 blockers" and "Amide derivatives as Nav1.7 and Nav1.8 blockers." Both inventions focus on compounds that exhibit blocking activities of voltage-gated sodium channels, specifically Nav1.7 and Nav1.8. These compounds are useful in the treatment or prevention of disorders where these channels play a critical role. The inventions also encompass pharmaceutical compositions that include these compounds, highlighting their potential therapeutic applications.

Career Highlights

Throughout his career, Yuji Shishido has worked with leading pharmaceutical companies, including Pfizer Corporation and Raqualia Pharma Inc. His experience in these organizations has allowed him to refine his expertise in drug development and innovation.

Collaborations

Shishido has collaborated with notable colleagues in the field, including Tadashi Inoue and Satoshi Nagayama. These partnerships have contributed to the advancement of his research and the successful development of his patented inventions.

Conclusion

Yuji Shishido's contributions to the field of pharmaceuticals through his innovative patents demonstrate his commitment to advancing medical science. His work on voltage-gated sodium channel blockers holds promise for the treatment of various medical conditions.

This text is generated by artificial intelligence and may not be accurate.